AMRN Amarin Corporation plc - American Depositary Shares
$13,99
Fiyat · Ağu 18, 2026
Temel veriler itibarıyla Tem 29, 2026
52 Haftlık Aralık
$13–$21
13% of range
Analist Derecelendirmesi
HOLD
6 analysts
Fiyat Hedefi
$12
P/E (TTM)
-155.4
ROE
-8.4%
Net Kâr Marjı
-18.2%
Amarin Corporation plc - American Depositary Shares Hakkında Wikipedia'dan şirket genel bakışı
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
Devamını oku
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.
History
Amarin Corporation plc (formerly Ethical Holdings plc) was originally incorporated in England as a private limited company on March 1, 1989, and later re-registered as a public company on March 19, 1993. In 2002, the company suffered losses worth $37 million; 2003 losses exceeded $19 million. As of 2005, it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.
In December 2007, Amarin acquired Ester Neurosciences Limited for US$8.1 million. In 2011, CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.
Products and development
Vascepa (USA) / Vazkepa (EU)
Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease....Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.
Furthermore, VASCEPA® is in use in clinical trials by 3rd parties to see, if it has an effect on Alzheimer, Colon Cancer, Nonalcoholic Steatohepatitis (NASH), and other diseases.
HLS Therapeutics, Amarin´s license partner in Canada, presented results of their COVID-19 clinical trial for Vascepa at National Lipid Association Scientific Sessions 2020, December 12. The results demonstrated a 25% reduction of hs-CRP, a biomarker for inflammation. Most people with COVID-19 die, because of a cytokine storm, which causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines. Two more COVID-19 studies are actually running with Vascepa to validate and proof further benefits.
On January 28, the Committee for Medicinal Products for Human Use gave a positive recommendation for Vazcepa (its name in the EU), which the European Commission finally approved on March 30.
Patent disputes
On March 30, 2020, the designated patent judge in the U.S. District Court for the District of Nevada, Miranda Du, ruled for generic-drug makers Hikma Pharmaceuticals and Dr. Reddy's Laboratories in a lawsuit with Amarin over patents on Amarin's drug, Vascepa. Soon after, on April 2, 2020, Amarin filed an appeal of the ruling. The appeal was lost and an en-banc was also not granted, afterwards. On November 30, three weeks after Hikma Pharmaceuticals started the distribution of their generic version of Vascepa, Amarin filed a complaint of patent infringement against Hikma. On February 11, 2021, Amarin filed a petition for certiorari with the US Supreme Court. On June 21, 2021, the petition was denied.
== Finance ==
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
AMRN Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$13.99
Piyasa Değeri
$5.82B
P/E (TTM)
-155.4
EPS (TTM)
$-0.09
Gelir (TTM)
$214M
Temettü Verimi
—
ROE
-8.4%
D/E Borç/Özsermaye
—
52 Haftlık Aralık
$13 – $21
AMRN Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
$214M
2016-12-31
→
2025-12-31
Hisse Başına Kâr
$-0.09
2016-12-31
→
2025-12-31
Serbest Nakit Akışı
—
2016-12-31
→
2020-12-31
Marjlar
-18.2%
2016-12-31
→
2025-12-31
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
AMRN
Akran Ortalaması
P/E (TTM)
-155.4
55.9
P/S (TTM) (F/S (TTM))
27.3
5.5
P/B (F/D)
12.7
1.8
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
AMRN
Akran Ortalaması
Gross Margin (Brüt Kar Marjı)
56.6%
63.8%
Operating Margin (Faaliyet Kâr Marjı)
-23.5%
—
Net Profit Margin (Net Kâr Marjı)
-18.2%
-14.2%
ROA
-5.7%
-4.2%
ROE
-8.4%
-6.0%
ROIC
-11.8%
—
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
AMRN
Akran Ortalaması
Current Ratio (Cari Oran)
3.3
3.7
Quick Ratio (Cari Oran)
2.2
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
AMRN
Akran Ortalaması
Revenue YoY (Gelir Yıllık Bazda)
-6.6%
—
Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı)
-16.7%
—
Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı)
-19.0%
—
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
AMRN
Akran Ortalaması
AMRN Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
SAT
6 analist
- Güçlü Al 0 0,0%
- Al 0 0,0%
- Tut 2 33,3%
- Sat 2 33,3%
- Güçlü Sat 2 33,3%
12 Aylık Fiyat Hedefi
1 analist · 2026-08-15
Düşük
$12.00
Yüksek
$12.00
Medyan hedef
$12.00
-14,2%
Ortalama hedef
$12.00
-14,2%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
0.20%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 30 Haziran 2026 | $0.04 | $-0.01 | 0.05% |
| 31 Mart 2026 | $-0.09 | $0.09 | -0.18% |
| 31 Aralık 2025 | $0.01 | $0.00 | 0.01% |
| 30 Eylül 2025 | $0.08 | $-0.58 | 0.66% |
| 30 Haziran 2025 | $0.66 | $-0.18 | 0.84% |
| 31 Mart 2025 | $-0.76 | $-0.58 | -0.18% |
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| AMRN | $5.81B | -155.1 | -6.6% | -18.2% | -8.4% | 56.6% |
| ALKS | $4.63B | 19.6 | -5.2% | 16.4% | 14.0% | — |
| PRTA | $514M | -2.1 | -92.8% | -2520.6% | -63.6% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 18
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $214M | $229M | $307M | $369M | $583M | $614M | $430M | $229M | $181M | $130M | $82M | $54M | |
| Cost of Revenue | · | · | · | · | $121M | $131M | $96M | $55M | $45M | $34M | $28M | $20M | |
| Gross Profit | $121M | $81M | $166M | $242M | $462M | $483M | $334M | $175M | $136M | $96M | $54M | $34M | |
| R&D Expense | $20M | $21M | $22M | $30M | $29M | $39M | $34M | $56M | $47M | $50M | $51M | $50M | |
| SG&A Expense | $115M | $152M | $200M | $304M | $408M | $463M | $324M | $227M | $135M | $111M | $101M | $79M | |
| Operating Expenses | $171M | $173M | $233M | $348M | $451M | $502M | $358M | $283M | $182M | $161M | $152M | $130M | |
| Operating Income | $-50M | $-92M | $-68M | $-106M | $11M | $-20M | $-24M | $-108M | $-46M | $-66M | $-98M | $-96M | |
| Interest Expense | $7.0K | $7.0K | $8.0K | $15.0K | $129.0K | $3M | $7M | $9M | $10M | $19M | $20M | $19M | |
| Interest Income | $11M | $13M | $12M | $3M | $1M | $5M | $8M | $1M | $429.0K | $234.0K | $132.0K | $96.0K | |
| Other Non-op | $3M | $1M | $2M | $-740.0K | $-302.0K | $104.0K | $-75.0K | $-326.0K | $74.0K | $-482.0K | $-228.0K | $4M | |
| Pretax Income | $-36M | $-77M | $-54M | $-104M | $11M | $-17M | $-22M | $-116M | $-55M | $-76M | $-118M | $-59M | |
| Income Tax | $3M | $5M | $5M | $2M | $4M | $745.0K | $164.0K | $96.0K | $13M | $10M | $-3M | $-3M | |
| Net Income | $-39M | $-82M | $-59M | $-106M | $8M | $-18M | $-23M | $-116M | $-68M | $-86M | $-115M | $-56M | |
| EPS (Basic) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 | $-0.83 | $-0.32 | |
| EPS (Diluted) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 | $-0.83 | $-0.36 | |
| Shares (Basic) | 414,984,000 | 410,937,000 | 407,655,000 | 401,155,000 | 395,992,000 | 381,759,000 | 342,538,000 | 297,237,000 | 270,652,000 | 211,874,000 | 180,654,000 | 173,719,000 | |
| Shares (Diluted) | 414,984,000 | 410,937,000 | 407,655,000 | 401,155,000 | 402,480,000 | 381,759,000 | 342,538,000 | 297,237,000 | 270,652,000 | 211,874,000 | 180,654,000 | 173,824,000 | |
| EBITDA | $-50M | $-92M | $-68M | · | · | $-20M | · | $-108M | $-46M | $-66M | $-98M | $-96M |
Bilanço 27
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $135M | $121M | $199M | $218M | $219M | $187M | $645M | $249M | $74M | $98M | $107M | $120M | |
| Short-term Investments | $168M | $173M | $121M | $92M | $235M | $314M | · | · | · | · | · | · | |
| Receivables | $127M | $122M | $134M | $131M | $164M | $155M | $116M | $67M | $45M | $20M | $14M | $8M | |
| Inventory | $196M | $166M | $259M | $229M | $235M | $189M | $77M | $58M | $30M | $21M | $19M | $14M | |
| Prepaid Expense | $24M | $13M | $12M | $19M | $22M | $31M | $13M | $3M | $3M | $7M | $3M | $3M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| Current Assets | $650M | $595M | $725M | $689M | $879M | $879M | $855M | $378M | $153M | $146M | $144M | $145M | |
| PP&E (Net) | $12.0K | $16.0K | $114.0K | $874.0K | $1M | $2M | $2M | $63.0K | $28.0K | $78.0K | $243.0K | $381.0K | |
| PP&E (Gross) | $1M | $1M | $1M | $3M | $3M | $4M | $3M | $902.0K | $844.0K | $821.0K | $997.0K | $969.0K | |
| Accum. Depreciation | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $839.0K | $816.0K | $755.0K | $754.0K | $588.0K | |
| Intangibles | $13M | $16M | $19M | $22M | $24M | $14M | $15M | $7M | $8M | $9M | $9M | $10M | |
| Other Non-current Assets | $1M | $1M | $1M | $458.0K | $456.0K | $432.0K | $1M | $174.0K | $174.0K | $741.0K | $174.0K | $3M | |
| Total Assets | $671M | $685M | $832M | $886M | $1.07B | $966M | $882M | $386M | $162M | $167M | $173M | $171M | |
| Accounts Payable | $45M | $40M | $53M | $65M | $115M | $106M | $50M | $38M | $25M | $6M | $11M | $9M | |
| Current Liabilities | $194M | $180M | $259M | $259M | $371M | $307M | $242M | $157M | $109M | $76M | $51M | $40M | |
| Capital Leases | $6M | $8M | $9M | $10M | $9M | $9M | $9M | · | · | · | · | · | |
| Other Non-current Liabilities | $11M | $12M | $9M | $8M | $8M | $6M | $4M | $11M | $1M | $710.0K | $335.0K | $386.0K | |
| Total Liabilities | $211M | $199M | $280M | $291M | $401M | $339M | $274M | $233M | $227M | $176M | $301M | $260M | |
| Long-term Debt | · | · | · | · | · | · | $50M | $80M | $92M | $94M | $92M | $105M | |
| Total Debt | · | · | · | · | · | $0 | · | $80M | $93M | $101M | $106M | $105M | |
| Common Stock | $310M | $305M | $303M | $299M | $294M | $290M | $269M | $247M | $209M | $207M | $150M | $143M | |
| Paid-in Capital | $1.92B | $1.91B | $1.90B | $1.89B | $1.86B | $1.82B | $1.76B | $1.28B | $978M | · | · | · | |
| Retained Earnings | $-1.71B | $-1.67B | $-1.59B | $-1.53B | $-1.42B | $-1.43B | $-1.41B | $-1.39B | $-1.27B | $-1.20B | $-1.12B | $-970M | |
| Treasury Stock | $67M | $65M | $64M | $62M | $61M | $51M | $36M | $10M | $4M | $1M | $411.0K | $217.0K | |
| Stockholders' Equity | $459M | $486M | $552M | $595M | $667M | $628M | $608M | $152M | $-65M | $-9M | $-129M | $-88M | |
| Liabilities + Equity | $671M | $685M | $832M | $886M | $1.07B | $966M | $882M | $386M | $162M | $167M | $173M | $171M | |
| Shares Outstanding | 416,214,102 | 411,584,851 | 408,824,093 | 408,824,093 | 396,598,008 | 392,538,081 | 360,103,901 | 325,850,013 | 271,022,011 | 269,363,696 | 183,403,263 | 174,590,372 |
Nakit Akışı 17
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $23.0K | $62.0K | $138.0K | $166.0K | $198.0K | |
| Stock-based Comp | $14M | $18M | $16M | $26M | $37M | $46M | $31M | $19M | $14M | $14M | $14M | $9M | |
| Deferred Tax | · | · | · | · | · | · | · | · | $11M | $9M | $-4M | $-4M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $2M | $1M | $679.0K | $646.0K | $646.0K | $645.0K | $646.0K | $646.0K | |
| Restructuring | $36M | $0 | $11M | $14M | $14M | · | · | · | · | · | · | · | |
| Operating Cash Flow | $7M | $-31M | $7M | $-180M | $-67M | $-22M | $-9M | $-95M | $-33M | $-72M | $-84M | $-75M | |
| CapEx | · | · | · | · | · | $252.0K | $2M | $58.0K | $12.0K | $21.0K | $28.0K | · | |
| Investing Cash Flow | $9M | $-46M | $-26M | $175M | $104M | $-377M | $-2M | $-58.0K | $-12.0K | $-21.0K | · | · | |
| Net Debt Issued | · | · | · | · | · | $-50M | · | $-15M | $-3M | · | · | · | |
| Stock Issued | · | · | · | · | · | · | $440M | $265M | · | $65M | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | $194.0K | · | |
| Net Stock Activity | · | · | · | · | · | · | · | $265M | · | $65M | $-194.0K | · | |
| Financing Cash Flow | $-2M | $-1M | $230.0K | $-379.0K | $-5M | $-59M | $410M | $271M | $8M | $63M | · | · | |
| Net Change in Cash | $14M | $-78M | $-18M | $-5M | $32M | $-458M | $398M | $176M | $-25M | $-9M | $-13M | $-72M | |
| Taxes Paid | $1M | $4M | $2M | $-2M | $4M | $-207.0K | $-67.0K | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | $-22M | · | $-95M | $-33M | $-72M | $-85M | · | |
| Levered FCF | · | · | · | · | · | $-25M | · | $-104M | $-45M | $-93M | $-104M | · |
Kârlılık 8
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.6% | 35.6% | 53.9% | · | · | 78.6% | · | 76.2% | 75.2% | 73.6% | 65.9% | 62.2% | |
| Operating Margin | -23.5% | -40.2% | -22.0% | · | · | -3.2% | · | -47.2% | -25.1% | -50.4% | -120.1% | -177.0% | |
| Net Margin | -18.2% | -35.9% | -19.3% | · | · | -2.9% | · | -50.8% | -37.5% | -66.4% | -140.9% | -104.0% | |
| Pretax Margin | -16.9% | -33.8% | -17.5% | · | · | -2.8% | · | -50.8% | -30.3% | -58.7% | -144.7% | -109.2% | |
| EBITDA Margin | -23.5% | -40.2% | -22.0% | · | · | -3.2% | · | -47.2% | -25.1% | -50.4% | -120.1% | -177.0% | |
| ROA | -5.7% | -10.8% | -6.9% | · | · | -1.9% | · | -42.5% | -41.3% | -50.8% | -66.9% | -26.6% | |
| ROE | -8.4% | -16.2% | -10.7% | · | · | -2.9% | · | -234.1% | 183.0% | 124.9% | 105.9% | 92.2% | |
| ROIC | -11.8% | -20.1% | -13.5% | · | · | -3.3% | · | -46.6% | -200.8% | -80.6% | 417.0% | -551.6% |
Likidite ve Solventlik 5
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.3 | 2.8 | · | · | 2.9 | · | 2.4 | 1.4 | 1.9 | 2.8 | 3.6 | |
| Quick Ratio | 2.2 | 2.3 | 1.8 | · | · | 2.1 | · | 2.0 | 1.1 | 1.6 | 2.4 | 3.2 | |
| Debt / Equity | · | · | · | · | · | 0.0 | · | 0.5 | -1.4 | -11.2 | -0.8 | -1.2 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 0.3 | -1.1 | -9.4 | -0.7 | -1.0 | |
| Interest Coverage | -7167.1 | -13113.9 | -8448.5 | · | · | -7.5 | · | -12.2 | -4.7 | -3.5 | -4.9 | -5.2 |
Verimlilik 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | 0.4 | · | · | 0.7 | · | 0.8 | 1.1 | 0.8 | 0.5 | 0.3 | |
| Inventory Turnover | · | · | · | · | · | 1.0 | · | 1.2 | 1.8 | 1.7 | 1.7 | 1.2 | |
| Receivables Turnover | 1.7 | 1.8 | 2.3 | · | · | 4.5 | · | 4.1 | 5.5 | 7.7 | 7.5 | 9.4 |
Büyüme Oranları 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -6.6% | -25.5% | -16.9% | -36.7% | -5.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -16.7% | -26.8% | -20.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -19.0% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM) 14
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $214M | $229M | $307M | $369M | $583M | $614M | $430M | $229M | $181M | $130M | $82M | $54M | |
| Net Income TTM | $-39M | $-82M | $-59M | $-106M | $8M | $-18M | $-23M | $-116M | $-68M | $-86M | $-115M | $-56M | |
| Market Cap | $5.81B | $4.03B | $7.11B | · | · | $38.39B | · | $88.70B | $21.74B | $16.59B | $6.93B | $3.42B | |
| Enterprise Value | · | · | · | · | · | $37.89B | · | $88.53B | $21.76B | $16.60B | $6.93B | $3.41B | |
| P/E | -155.1 | -49.0 | -116.0 | -93.1 | 3370.0 | -1956.0 | -6125.7 | -697.9 | -320.8 | -150.2 | -45.5 | -54.4 | |
| P/S | 27.2 | 17.6 | 23.2 | · | · | 62.5 | · | 387.0 | 120.0 | 127.6 | 84.8 | 63.1 | |
| P/B | 12.7 | 8.3 | 12.9 | · | · | 61.2 | · | 582.3 | -333.9 | -1831.8 | -53.7 | -38.7 | |
| P / Tangible Book | 13.0 | 8.6 | 13.4 | 17.1 | 41.5 | 62.6 | · | · | · | · | · | · | |
| P / Cash Flow | 863.6 | -130.0 | 1033.9 | · | · | -1765.4 | · | -936.6 | -661.9 | -231.0 | -81.8 | -47.3 | |
| P / FCF | · | · | · | · | · | -1745.2 | · | -936.0 | -661.7 | -231.0 | -81.8 | · | |
| EV / EBITDA | · | · | · | · | · | -1927.7 | · | -818.0 | -477.6 | -252.9 | -70.6 | -35.5 | |
| EV / FCF | · | · | · | · | · | -1722.4 | · | -934.2 | -662.3 | -231.0 | -81.8 | · | |
| EV / Revenue | · | · | · | · | · | 61.7 | · | 386.2 | 120.1 | 127.6 | 84.8 | 62.9 | |
| Earnings Yield | -0.64% | -2.0% | -0.86% | -1.1% | 0.03% | -0.05% | -0.02% | -0.14% | -0.31% | -0.67% | -2.2% | -1.8% |
Gelir Tablosu 16
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42M | $45M | $49M | $50M | $73M | $42M | $62M | $42M | $67M | $57M | $75M | $66M | $80M | $86M | $90M | $90M | |
| Gross Profit | $15M | $18M | $23M | $22M | $50M | $25M | $-10M | $16M | $43M | $32M | $45M | $30M | $43M | $48M | $64M | $63M | |
| R&D Expense | $5M | $5M | $5M | $4M | $5M | $5M | $6M | $5M | $5M | $6M | $6M | $5M | $6M | $6M | $5M | $6M | |
| SG&A Expense | $22M | $21M | $20M | $20M | $39M | $37M | $37M | $37M | $39M | $40M | $44M | $45M | $51M | $60M | $68M | $59M | |
| Operating Expenses | $27M | $29M | $29M | $33M | $66M | $42M | $43M | $41M | $43M | $45M | $50M | $51M | $67M | $65M | $73M | $68M | |
| Operating Income | $-12M | $-11M | $-6M | $-11M | $-16M | $-17M | $-53M | $-25M | $-524.0K | $-14M | $-5M | $-21M | $-24M | $-17M | $-10M | $-5M | |
| Interest Income | $3M | $2M | · | · | $3M | $3M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $1M | $188.0K | $3M | $205.0K | $-85.0K | $253.0K | $-754.0K | $265.0K | $145.0K | $2M | $-1M | $-575.0K | $3M | $624.0K | $1M | $511.0K | |
| Pretax Income | $-8M | $-9M | $-853.0K | $-8M | $-13M | $-14M | $-50M | $-22M | $3M | $-9M | $-2M | $-19M | $-18M | $-14M | $-7M | $-4M | |
| Income Tax | $-219.0K | $2M | $371.0K | $-377.0K | $689.0K | $2M | $-1M | $4M | $1M | $1M | $3M | $501.0K | $-355.0K | $2M | $-8M | $1M | |
| Net Income | $-8M | $-11M | $-1M | $-8M | $-14M | $-16M | $-49M | $-25M | $2M | $-10M | $-6M | $-19M | $-18M | $-16M | $856.0K | $-5M | |
| EPS (Basic) | $-0.02 | $-0.03 | $0.00 | $-0.02 | $-0.03 | $-0.04 | $-0.12 | $-0.06 | $0.00 | $-0.02 | $-0.02 | $-0.05 | $-0.04 | $-0.04 | $0.01 | $-0.01 | |
| EPS (Diluted) | $-0.02 | $-0.03 | $0.00 | $-0.02 | $-0.03 | $-0.04 | $-0.12 | $-0.06 | $0.00 | $-0.02 | $-0.02 | $-0.05 | $-0.04 | $-0.04 | $0.01 | $-0.01 | |
| Shares (Basic) | 416,444,000 | 419,054,000 | -828,446,000 | 415,531,000 | 414,477,000 | 413,422,000 | -821,210,000 | 411,150,000 | 410,851,000 | 410,146,000 | -814,787,000 | 408,417,000 | 407,848,000 | 406,177,000 | -799,451,000 | 404,614,000 | |
| Shares (Diluted) | 416,444,000 | 419,054,000 | -828,446,000 | 415,531,000 | 414,477,000 | 413,422,000 | -821,754,000 | 411,150,000 | 411,395,000 | 410,146,000 | -814,787,000 | 408,417,000 | 407,848,000 | 406,177,000 | -799,451,000 | 404,614,000 | |
| EBITDA | $-12M | $-11M | · | $-11M | $-16M | $-17M | · | $-25M | $-524.0K | $-14M | · | $-21M | $-24M | $-17M | · | $-5M |
Bilanço 24
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $144M | $131M | $135M | $123M | $148M | $120M | $121M | $157M | $216M | $214M | · | $271M | $233M | $191M | · | $240M | |
| Short-term Investments | $171M | $177M | $168M | $164M | $151M | $162M | $173M | $149M | $91M | $94M | · | $50M | $80M | $113M | · | $63M | |
| Receivables | $93M | $108M | $127M | $127M | $119M | $107M | $122M | $113M | $124M | $116M | · | $122M | $123M | $133M | · | $123M | |
| Inventory | $164M | $184M | $196M | $185M | $171M | $159M | $166M | $224M | $239M | $255M | · | $254M | $227M | $226M | · | $228M | |
| Prepaid Expense | $31M | $26M | $24M | $29M | $17M | $25M | $13M | $7M | $32M | $8M | · | $19M | $43M | $20M | · | $28M | |
| Current Assets | $603M | $626M | $650M | $628M | $607M | $573M | $595M | $650M | $702M | $688M | · | $718M | $706M | $684M | · | $687M | |
| PP&E (Net) | · | · | $12.0K | $13.0K | $14.0K | $15.0K | $16.0K | $24.0K | $49.0K | $81.0K | · | $147.0K | $179.0K | $187.0K | · | $999.0K | |
| PP&E (Gross) | · | · | $1M | · | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $1M | · | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $12M | $13M | $13M | $14M | $15M | $16M | $16M | $17M | $18M | $19M | · | $20M | $20M | $21M | · | $22M | |
| Other Non-current Assets | $4M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $2M | $2M | · | $456.0K | |
| Total Assets | $624M | $646M | $671M | $660M | $670M | $656M | $685M | $751M | $800M | $790M | · | $839M | $860M | $860M | · | $908M | |
| Accounts Payable | $19M | $48M | $45M | $37M | $45M | $46M | $40M | $41M | $54M | $68M | · | $53M | $54M | $59M | · | $93M | |
| Current Liabilities | $164M | $180M | $194M | $182M | $186M | $162M | $180M | $202M | $231M | $224M | · | $267M | $271M | $244M | · | $287M | |
| Capital Leases | $5M | $6M | $6M | $7M | $7M | $8M | $8M | $8M | $8M | $8M | · | $9M | $9M | $10M | · | $10M | |
| Other Non-current Liabilities | $11M | $11M | $11M | $12M | $12M | $12M | $12M | $9M | $9M | $9M | · | $7M | $7M | $9M | · | $10M | |
| Total Liabilities | $181M | $196M | $211M | $201M | $205M | $182M | $199M | $219M | $248M | $244M | · | $286M | $291M | $275M | · | $320M | |
| Common Stock | $315M | $314M | $310M | $310M | $309M | $308M | $305M | $305M | $305M | $305M | · | $302M | $302M | $301M | · | $299M | |
| Paid-in Capital | $1.92B | $1.92B | $1.92B | $1.92B | $1.92B | $1.92B | $1.91B | $1.91B | $1.91B | $1.90B | · | $1.90B | $1.89B | $1.89B | · | $1.88B | |
| Retained Earnings | $-1.73B | $-1.72B | $-1.71B | $-1.71B | $-1.70B | $-1.68B | $-1.67B | $-1.62B | $-1.59B | $-1.60B | · | $-1.58B | $-1.56B | $-1.54B | · | $-1.53B | |
| Treasury Stock | $69M | $69M | $67M | $67M | $67M | $66M | $65M | $65M | $65M | $65M | · | $64M | $63M | $63M | · | $62M | |
| Stockholders' Equity | $444M | $449M | $459M | $459M | $465M | $474M | $486M | $531M | $552M | $546M | $552M | $553M | $569M | $585M | $595M | $588M | |
| Liabilities + Equity | $624M | $646M | $671M | $660M | $670M | $656M | $685M | $751M | $800M | $790M | · | $839M | $860M | $860M | · | $908M | |
| Shares Outstanding | 420,044,022 | 419,594,602 | 416,214,102 | 415,965,977 | 415,401,497 | 414,365,189 | 411,584,851 | 411,261,678 | 411,113,770 | 410,735,780 | · | 408,551,020 | 408,133,807 | 407,265,944 | 408,824,093 | 403,828,955 |
Nakit Akışı 9
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $6M | $4M | $3M | $5M | $4M | $5M | $5M | $4M | $2M | $6M | $7M | $5M | |
| Amort. of Intangibles | $636.0K | $637.0K | $701.0K | $866.0K | $728.0K | $729.0K | $729.0K | $728.0K | $729.0K | $729.0K | $701.0K | $701.0K | $701.0K | $702.0K | $636.0K | $636.0K | |
| Restructuring | $40.0K | $3M | $4M | $9M | $23M | · | · | · | · | · | $229.0K | $711.0K | $10M | · | $-180.0K | $3M | |
| Operating Cash Flow | $7M | $6M | $15M | $-13M | $17M | $-12M | $-13M | $-2M | $-3M | $-13M | $-645.0K | $7M | $7M | $-7M | $2M | $-18M | |
| Investing Cash Flow | $6M | $-8M | $-4M | $-12M | $12M | $12M | $-23M | $-57M | $5M | $29M | $-71M | $31M | $34M | $-20M | $-28M | $31M | |
| Stock Issued | · | · | · | · | · | · | · | $0 | · | · | · | $0 | · | · | · | $0 | |
| Financing Cash Flow | $-247.0K | $-2M | $-4.0K | $-248.0K | $-663.0K | $-1M | $17.0K | $-68.0K | $34.0K | $-1M | $83.0K | $-277.0K | $60.0K | $364.0K | $38.0K | $-156.0K | |
| Net Change in Cash | $12M | $-4M | $12M | $-25M | $28M | $-2M | $-36M | $-59M | $2M | $15M | $-72M | $38M | $42M | $-26M | $-26M | $12M | |
| Taxes Paid | $1M | $2M | $1M | $-1.0K | $-169.0K | $22.0K | $6M | $-1M | $-698.0K | $29.0K | $3M | $-432.0K | $-633.0K | $38.0K | $-292.0K | $622.0K |
Kârlılık 8
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.5% | 39.4% | · | 44.7% | 69.2% | 59.8% | · | 38.5% | 63.4% | 56.5% | · | 45.1% | 53.2% | 55.8% | · | 69.9% | |
| Operating Margin | -28.4% | -25.1% | · | -22.4% | -22.0% | -39.9% | · | -59.5% | -0.78% | -24.0% | · | -32.5% | -29.9% | -20.2% | · | -5.7% | |
| Net Margin | -18.1% | -23.3% | · | -15.6% | -19.4% | -37.4% | · | -59.4% | 2.3% | -17.6% | · | -29.2% | -21.9% | -19.1% | · | -5.7% | |
| Pretax Margin | -18.6% | -19.3% | · | -16.3% | -18.5% | -32.4% | · | -50.9% | 4.3% | -15.3% | · | -28.5% | -22.4% | -16.9% | · | -4.3% | |
| EBITDA Margin | -28.4% | -25.1% | · | -22.4% | -22.0% | -39.9% | · | -59.5% | -0.78% | -24.0% | · | -32.5% | -29.9% | -20.2% | · | -5.7% | |
| ROA | -1.2% | -1.6% | · | -1.1% | -1.9% | -2.2% | · | -3.2% | 0.18% | -1.2% | · | -2.2% | -1.9% | -1.8% | · | -0.53% | |
| ROE | -1.7% | -2.3% | · | -1.6% | -2.8% | -3.1% | · | -4.6% | 0.27% | -1.8% | · | -3.4% | -3.1% | -2.7% | · | -0.84% | |
| ROIC | -2.6% | -3.0% | · | -2.3% | -3.6% | -4.1% | · | -5.5% | -0.05% | -2.9% | · | -4.0% | -4.1% | -3.4% | · | -1.2% |
Likidite ve Solventlik 2
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 3.5 | · | 3.4 | 3.3 | 3.5 | · | 3.2 | 3.0 | 3.1 | · | 2.7 | 2.6 | 2.8 | · | 2.4 | |
| Quick Ratio | 2.5 | 2.3 | · | 2.3 | 2.2 | 2.4 | · | 2.1 | 1.9 | 1.9 | · | 1.7 | 1.6 | 1.8 | · | 1.5 |
Verimlilik 2
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 0.4 | 0.4 | · | 0.4 | 0.6 | 0.4 | · | 0.4 | 0.5 | 0.5 | · | 0.5 | 0.6 | 0.7 | · | 0.7 |
Değerleme (TTM) 9
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $210M | $210M | · | $207M | $225M | $208M | · | $232M | $270M | $289M | · | $322M | $350M | $365M | · | $421M | |
| Net Income TTM | $-40M | $-48M | · | $-63M | $-53M | $-49M | · | $-53M | $-45M | $-63M | · | $-58M | $-109M | $-123M | · | $-120M | |
| Market Cap | $6.70B | $6.07B | · | $6.81B | $6.74B | $3.73B | · | $5.18B | $5.67B | $7.31B | · | $7.52B | $9.71B | $12.22B | · | $8.80B | |
| P/E | -159.4 | -120.5 | · | -109.2 | -124.8 | -75.0 | · | -96.9 | -125.5 | -118.7 | · | -131.4 | -88.1 | -96.8 | · | -72.7 | |
| P/S | 31.9 | 29.0 | · | 33.0 | 30.0 | 17.9 | · | 22.3 | 21.0 | 25.3 | · | 23.3 | 27.7 | 33.5 | · | 20.9 | |
| P/B | 15.1 | 13.5 | · | 14.8 | 14.5 | 7.9 | · | 9.8 | 10.3 | 13.4 | · | 13.6 | 17.1 | 20.9 | · | 15.0 | |
| P / Tangible Book | 15.5 | 13.9 | · | 15.3 | 15.0 | 8.1 | · | 10.1 | 10.6 | 13.9 | · | 14.1 | 17.7 | 21.7 | · | 15.5 | |
| P / Cash Flow | · | 949.8 | · | · | · | -299.3 | · | · | · | -580.2 | · | · | · | -1743.4 | · | · | |
| Earnings Yield | -0.63% | -0.83% | · | -0.92% | -0.80% | -1.3% | · | -1.0% | -0.80% | -0.84% | · | -0.76% | -1.1% | -1.0% | · | -1.4% |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Gelir | $214M | $229M | $307M | $369M | $583M |
| Brüt Kâr Marjı % | 56.6% | 35.6% | 53.9% | — | — |
| Faaliyet Kâr Marjı % | -23.5% | -40.2% | -22.0% | — | — |
| Net Gelir | $-39M | $-82M | $-59M | $-106M | $8M |
| Seyreltilmiş Hisse Başı Kâr | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Cari Oran | 3.3 | 3.3 | 2.8 | — | — |
| Cari Oran | 2.2 | 2.3 | 1.8 | — | — |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kurumsal Sahipler (13F) 90 dosya · $59.1M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 23 (+15 önceki Ç'ye göre) | 7 (-12 önceki Ç'ye göre) | 19 (+1 önceki Ç'ye göre) | 10 (-3 önceki Ç'ye göre) | +89K |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| Sarissa Capital Management LP | $26.673.916 | 1.673.395 | 45,11% | Hisse senetleri |
| Kynam Capital Management, LP | $8.495.733 | 532.982 | 14,37% | Hisse senetleri |
| Waterfront Wealth Inc. | $3.183.561 | 213.949 | 5,38% | Hisse senetleri |
| Brooklands Fund Management Ltd | $2.741.449 | 177.325 | 4,64% | Hisse senetleri |
| Eversept Partners, LP | $2.316.018 | 145.296 | 3,92% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $1.845.980 | 115.808 | 3,12% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $1.602.145 | 100.511 | 2,71% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $1.144.699 | 71.813 | 1,94% | Hisse senetleri |
| CITADEL ADVISORS LLC | $971.671 | 60.958 | 1,64% | Hisse senetleri |
| LCM Capital Management Inc | $818.710 | 51.362 | 1,38% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $771.002 | 48.369 | 1,30% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $765.120 | 48.000 | 1,29% | Alım opsiyonu |
| George Kaiser Family Foundation | $593.080 | 37.207 | 1,00% | Hisse senetleri |
| JANE STREET GROUP, LLC | $523.294 | 32.829 | 0,89% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $516.265 | 36.995 | 0,87% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $462.276 | 29.001 | 0,78% | Hisse senetleri |
| STATE STREET CORP | $398.755 | 25.016 | 0,67% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $385.748 | 24.200 | 0,65% | Satım opsiyonu |
| Bleakley Financial Group, LLC | $374.670 | 23.505 | 0,63% | Hisse senetleri |
| State of New Jersey Common Pension Fund D | $300.931 | 18.879 | 0,51% | Hisse senetleri |
| CITADEL ADVISORS LLC | $299.672 | 18.800 | 0,51% | Satım opsiyonu |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | $292.818 | 18.370 | 0,50% | Hisse senetleri |
| R Squared Ltd | $269.992 | 16.938 | 0,46% | Hisse senetleri |
| State of Tennessee, Department of Treasury | $239.164 | 15.004 | 0,40% | Hisse senetleri |
| MORGAN STANLEY | $237.618 | 14.907 | 0,40% | Hisse senetleri |
| Quadrature Capital Ltd | $236.581 | 14.842 | 0,40% | Hisse senetleri |
| Quinn Opportunity Partners LLC | $228.022 | 14.305 | 0,39% | Hisse senetleri |
| Cubist Systematic Strategies, LLC | $224.390 | 13.699 | 0,38% | Hisse senetleri |
| EntryPoint Capital, LLC | $194.882 | 12.226 | 0,33% | Hisse senetleri |
| Jump Financial, LLC | $191.407 | 12.008 | 0,32% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $187.629 | 11.771 | 0,32% | Hisse senetleri |
| WELLS FARGO & COMPANY/MN | $179.564 | 11.265 | 0,30% | Hisse senetleri |
| NJ State Employees Deferred Compensation Plan | $178.542 | 10.900 | 0,30% | Hisse senetleri |
| Verdad Advisers, LP | $166.270 | 10.431 | 0,28% | Hisse senetleri |
| CITADEL ADVISORS LLC | $164.182 | 10.300 | 0,28% | Alım opsiyonu |
| Steward Partners Investment Advisory, LLC | $142.025 | 8.910 | 0,24% | Hisse senetleri |
| NEW YORK STATE COMMON RETIREMENT FUND | $121.224 | 7.605 | 0,21% | Hisse senetleri |
| OSAIC HOLDINGS, INC. | $104.537 | 6.559 | 0,18% | Hisse senetleri |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $92.038 | 5.774 | 0,16% | Hisse senetleri |
| MERCER GLOBAL ADVISORS INC /ADV | $80.099 | 5.025 | 0,14% | Hisse senetleri |
| UBS Group AG | $67.171 | 4.214 | 0,11% | Hisse senetleri |
| RHUMBLINE ADVISERS | $59.498 | 3.733 | 0,10% | Hisse senetleri |
| NATIONAL BANK OF CANADA /FI/ | $40.137 | 2.518 | 0,07% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $30.318 | 1.902 | 0,05% | Hisse senetleri |
| ROYAL BANK OF CANADA | $28.000 | 1.787 | 0,05% | Hisse senetleri |
| GAMMA Investing LLC | $25.121 | 1.576 | 0,04% | Hisse senetleri |
| RAYMOND JAMES FINANCIAL INC | $22.332 | 1.401 | 0,04% | Hisse senetleri |
| NewEdge Advisors, LLC | $21.471 | 1.347 | 0,04% | Hisse senetleri |
| Farther Finance Advisors, LLC | $15.271 | 958 | 0,03% | Hisse senetleri |
| BlackRock, Inc. | $13.677 | 858 | 0,02% | Hisse senetleri |
| IFP Advisors, Inc | $12.975 | 814 | 0,02% | Hisse senetleri |
| Beaird Harris Wealth Management, LLC | $11.955 | 750 | 0,02% | Hisse senetleri |
| ACADIAN ASSET MANAGEMENT LLC | $11.467 | 720.984 | 0,02% | Hisse senetleri |
| CoreCap Advisors, LLC | $8.528 | 535 | 0,01% | Hisse senetleri |
| Integrated Wealth Concepts LLC | $8.449 | 530 | 0,01% | Hisse senetleri |
| JONES FINANCIAL COMPANIES LLLP | $7.844 | 493 | 0,01% | Hisse senetleri |
| BARCLAYS PLC | $4.862 | 305 | 0,01% | Hisse senetleri |
| JPMORGAN CHASE & CO | $3.853 | 242 | 0,01% | Hisse senetleri |
| CWM, LLC | $3.644 | 252 | 0,01% | Hisse senetleri |
| Westside Investment Management, Inc. | $3.268 | 205 | 0,01% | Hisse senetleri |
| Global Retirement Partners, LLC | $2.646 | 166 | 0,00% | Hisse senetleri |
| GROUP ONE TRADING LLC | $2.072 | 130 | 0,00% | Hisse senetleri |
| HARBOUR INVESTMENTS, INC. | $1.562 | 98 | 0,00% | Hisse senetleri |
| Federation des caisses Desjardins du Quebec | $1.435 | 90 | 0,00% | Hisse senetleri |
| Activest Wealth Management | $797 | 50 | 0,00% | Hisse senetleri |
| HighMark Wealth Management LLC | $797 | 50 | 0,00% | Hisse senetleri |
| Arax Advisory Partners | $685 | 43 | 0,00% | Hisse senetleri |
| Darwin Wealth Management, LLC | $398 | 25 | 0,00% | Hisse senetleri |
| Continuum Advisory, LLC | $303 | 19 | 0,00% | Hisse senetleri |
| Caitong International Asset Management Co., Ltd | $271 | 17 | 0,00% | Hisse senetleri |
| SEI INVESTMENTS CO | $260 | 16 | 0,00% | Hisse senetleri |
| Hayek Kallen Investment Management | $204 | 12.809 | 0,00% | Hisse senetleri |
| Atlantic Union Bankshares Corp | $192 | 12 | 0,00% | Hisse senetleri |
| Truvestments Capital LLC | $191 | 12 | 0,00% | Hisse senetleri |
| Parallel Advisors, LLC | $159 | 10 | 0,00% | Hisse senetleri |
| Creative Capital Management Investments LLC | $143 | 9 | 0,00% | Hisse senetleri |
| Key Financial Inc | $128 | 8 | 0,00% | Hisse senetleri |
| CITIGROUP INC | $128 | 8 | 0,00% | Hisse senetleri |
| MCGUIRE CAPITAL ADVISORS INC | $112 | 7 | 0,00% | Hisse senetleri |
| EASTERN BANK | $112 | 7 | 0,00% | Hisse senetleri |
| Lindbrook Capital, LLC | $90 | 200 | 0,00% | Hisse senetleri |
| Oakmont Advisory Group, LLC | $80 | 5 | 0,00% | Hisse senetleri |
| Allworth Financial LP | $80 | 5 | 0,00% | Hisse senetleri |
| Crewe Advisors LLC | $80 | 5 | 0,00% | Hisse senetleri |
| BFSG, LLC | $80 | 5 | 0,00% | Hisse senetleri |
| SBI Securities Co., Ltd. | $80 | 5 | 0,00% | Hisse senetleri |
| WHITTIER TRUST CO | $63 | 4 | 0,00% | Hisse senetleri |
| Caitlin John, LLC | $32 | 2 | 0,00% | Hisse senetleri |
| WHITTIER TRUST CO OF NEVADA INC | $15 | 1 | 0,00% | Hisse senetleri |
| JFS WEALTH ADVISORS, LLC | $15 | 1 | 0,00% | Hisse senetleri |
Şirket yöneticileri 37 içeriden öğrenenler · 17 yöneticiler · 22 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Aaron Berg | President and CEO | 26 Haziran 2026 M | 85.648 | 0 | 0 | $0 |
| Patrick Holt | President and CEO | 22 Ocak 2024 P | 314.426 | 0 | 0 | $0 |
| Karim Mikhail | President and CEO | 21 Şubat 2023 A | 283.507 | 0 | 0 | $0 |
| John F Thero | President and CEO | 19 Kasım 2019 S | 2.342.285 | 0 | 0 | $0 |
| Peter L. Fishman | SVP, CFO | 01 Ağustos 2026 A | 7.619 | 0 | 0 | $0 |
| Thomas Charles Reilly | EVP and CFO | 01 Temmuz 2024 M | 94.305 | 0 | 0 | $0 |
| Michael Wayne Kalb | SVP and CFO | 16 Aralık 2019 M | 21.552 | 0 | 0 | $0 |
| David Paul Keenan | EVP, Chief Operating Officer | 01 Temmuz 2026 A | 13.470 | 0 | 0 | $0 |
| Jonathan Provoost | EVP, Chief Legal Officer | 01 Temmuz 2026 A | 4.624 | 0 | 0 | $0 |
| Steven B Ketchum | EVP, Chief Scientific Officer | 01 Temmuz 2026 A | 42.680 | 0 | 0 | $0 |
| Joseph T Kennedy | General Counsel | 07 Ekim 2019 F | 125.723 | 0 | 0 | $0 |
| Mark Salyer | Chief Commercial Officer | 01 Şubat 2018 A | — | 0 | 0 | $0 |
| Michael James Farrell | VP, Finance | 01 Şubat 2016 A | 30.190 | 0 | 0 | $0 |
| Paul Huff | Chief Commercial Officer | 26 Temmuz 2012 A | 0 | 0 | 0 | $0 |
| Stuart D Sedlack | Senior Vice President | 26 Temmuz 2012 A | 0 | 0 | 0 | $0 |
| Paresh Soni | SVP and Head of Development | 01 Şubat 2012 A | 0 | 0 | 0 | $0 |
| Frederick W Ahlholm | Vice President Finance | 01 Şubat 2012 A | 0 | 0 | 0 | $0 |
| Oliver O'Connor | Yönetim kurulu üyesi | 18 Nisan 2026 M | 801 | 0 | 0 | $0 |
| Paul Cohen | Yönetim kurulu üyesi | 18 Nisan 2026 M | 836 | 0 | 0 | $0 |
| Diane E. Sullivan | Yönetim kurulu üyesi | 18 Nisan 2026 M | 836 | 0 | 0 | $0 |
| Louis Sterling III | Yönetim kurulu üyesi | 18 Nisan 2026 M | 4.049 | 0 | 0 | $0 |
| Patrice Eadon Bonfiglio | Yönetim kurulu üyesi | 18 Nisan 2026 M | 836 | 0 | 0 | $0 |
| Keith Horn | Yönetim kurulu üyesi | 18 Nisan 2026 M | 836 | 0 | 0 | $0 |
| Odysseas D Kostas | Yönetim kurulu üyesi | 18 Nisan 2026 M | 836 | 0 | 0 | $0 |
| Mark Dipaolo | Yönetim kurulu üyesi | 18 Nisan 2025 M | 401 | 0 | 0 | $0 |
| Olsen Per Wold | Yönetim kurulu üyesi | 10 Ocak 2023 M | 171.027 | 0 | 0 | $0 |
| David M Stack | Yönetim kurulu üyesi | 04 Haziran 2021 P | 40.000 | 0 | 0 | $0 |
| Joseph S Zakrzewski | Yönetim kurulu üyesi | 03 Ocak 2020 M | 84.547 | 0 | 0 | $0 |
| Lars Ekman | Yönetim kurulu üyesi | 12 Kasım 2019 M | 0 | 0 | 0 | $0 |
| Kristine Peterson | Yönetim kurulu üyesi | 20 Mayıs 2019 A | 0 | 0 | 0 | $0 |
| Patrick J O'Sullivan | Yönetim kurulu üyesi | 20 Mayıs 2019 A | — | 0 | 0 | $0 |
| VAN HEEK G JAN | Yönetim kurulu üyesi | 20 Mayıs 2019 A | 14.168 | 0 | 0 | $0 |
| Dr. James I. Healy | Yönetim kurulu üyesi | 11 Temmuz 2016 A | 90.000 | 0 | 0 | $0 |
| GORDON CARL L | Yönetim kurulu üyesi | 04 Eylül 2012 S | 5.700 | 0 | 0 | $0 |
| Joseph Anderson | Yönetim kurulu üyesi | 10 Temmuz 2012 A | 11.683 | 0 | 0 | $0 |
| David W Feigal Jr | Yönetim kurulu üyesi | 12 Temmuz 2011 A | — | 0 | 0 | $0 |
| Abingworth LLP | 10% sahip | 19 Nisan 2012 S | 1.599.168 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
Aktivistler ve %5+ sahipler 34 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Sarissa Capital Management LP, Alexander J Denner ×3 başvurular | 25 Mart 2025 | 8,08% | Değişiklik | Yönetim kurulu kampanyası | SEC |
| 28 Şubat 2023 | — | İlk başvuru | — | SEC | |
| 27 Şubat 2023 | — | İlk başvuru | — | SEC | |
| 21 Şubat 2023 | — | İlk başvuru | — | SEC | |
| OR ×6 başvurular | 15 Şubat 2023 | — | İlk başvuru | — | SEC |
| 14 Şubat 2023 | — | İlk başvuru | — | SEC | |
| 10 Şubat 2023 | — | İlk başvuru | — | SEC | |
| 19 Ocak 2023 | — | İlk başvuru | — | SEC | |
| 16 Haziran 2022 | — | İlk başvuru | — | SEC | |
| Sofinnova Venture Partners VII, L.P. (“SVP VII”), Sofinnova Management VII, L.L.C. (“SM VII”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Eric P. Buatois (“Buatois”) ×4 başvurular | 23 Ağustos 2013 | — | İlk başvuru | — | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures V Co-Invest Growth Equity Fund LP 98-057-9772, Abingworth Bioventures V L.P. 98-051-8587, Abingworth Bioequities Master Fund Limited 66-066-0960 ×10 başvurular | 22 Temmuz 2013 | — | İlk başvuru | Yönetim kurulu kampanyası | SEC |
| Boxer Capital, LLC, Boxer Asset Management Inc., Joseph Lewis ×4 başvurular | 24 Ağustos 2011 | — | İlk başvuru | — | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP III LLC, Samuel D. Isaly ×14 başvurular | 28 Nisan 2011 | — | İlk başvuru | — | SEC |
| Fountain Healthcare Partners Fund 1, L.P. (“ Fountain ”), Fountain Healthcare Partners Ltd., Manus Rogan, Aidan King, Ena Prosser, Justin Lynch ×2 başvurular | 10 Aralık 2010 | — | İlk başvuru | — | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) | 26 Ekim 2010 | — | İlk başvuru | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.